6A41 - Substance or Medication-Induced Catatonia: Complete ICD-11 Coding Guide

1. Introduction

Substance- or medication-induced catatonia represents a complex neuropsychiatric syndrome that challenges healthcare professionals in various clinical contexts. Characterized by psychomotor disturbances ranging from extreme immobility to uncontrolled agitation, this condition emerges as a direct consequence of use, intoxication, or withdrawal from psychoactive substances and specific medications.

The clinical importance of this condition cannot be underestimated. Unlike other forms of catatonia, this variant has a clear temporal and causal relationship with exposure to external agents, which fundamentally alters both the diagnostic approach and therapeutic management. Precise identification of this syndrome is crucial to avoid inappropriate interventions that may worsen the clinical presentation.

The impact on public health is significant, especially considering the global increase in recreational psychoactive substance use and the widespread prescription of psychotropic medications. Professionals in emergency services, psychiatric units, and chemical dependency treatment clinics frequently encounter patients with substance-induced catatonic manifestations, making in-depth knowledge of this condition essential.

Correct coding using the ICD-11 code 6A41 is critical for multiple reasons: it ensures appropriate epidemiological recording, facilitates communication among professionals, guides appropriate therapeutic decisions, enables public health resource planning, and ensures proper legal documentation. Coding errors can result in inappropriate treatments, compromise clinical research, and cause significant administrative difficulties.

2. Correct ICD-11 Code

Code: 6A41

Description: Catatonia induced by substances or medications

Parent category: Catatonia (no specific higher code in the ICD-11 hierarchy)

Official definition: Catatonia induced by substances or medications is a syndrome of disturbances primarily of psychomotor activity, characterized by the co-occurrence of several symptoms of reduced, increased, or abnormal psychomotor activity that develops during or shortly after intoxication or withdrawal from some psychoactive substances, including phencyclidine (PCP), cannabis, hallucinogens such as mescaline or LSD, cocaine and MDMA or related drugs, or during the use of some psychoactive and non-psychoactive medications (e.g., antipsychotic medications, benzodiazepines, steroids, disulfiram, ciprofloxacin).

This code represents a specific diagnostic category within the classification of catatonic syndromes, distinguishing itself clearly from other forms of catatonia by its etiology directly related to pharmacological agents or substances of abuse. The ICD-11 classification recognizes the need to separately identify this condition due to its unique implications for treatment and prognosis.

The structure of code 6A41 allows precise documentation of the causal relationship between substance exposure and the development of catatonic symptoms, a fundamental element for appropriate clinical management. This coding also facilitates the identification of epidemiological patterns related to specific substances and medications that most frequently cause this syndrome.

3. When to Use This Code

The code 6A41 should be applied in specific clinical scenarios where there is clear evidence of temporal and causal relationship between exposure to substances or medications and the development of catatonic symptoms. Below are detailed practical situations:

Scenario 1: Catatonia following antipsychotic use A patient undergoing psychiatric treatment receives an increased dose of high-potency antipsychotic and, within 48 to 72 hours, develops mutism, catalepsy, and negativism. Neurological examination reveals no significant muscle rigidity or severe autonomic instability that would characterize neuroleptic malignant syndrome. The clear temporal relationship and absence of criteria for NMS justify the use of code 6A41.

Scenario 2: PCP intoxication A patient seen in an emergency department following recreational use of phencyclidine presents with maintained bizarre posture, motor stereotypies, echolalia, and waxy flexibility. There is no significant prior psychiatric history. Toxicological tests confirm the presence of PCP. Symptoms developed during the period of acute intoxication, establishing direct causal nexus with the substance.

Scenario 3: Benzodiazepine withdrawal An individual with prolonged benzodiazepine use at high doses abruptly discontinues the medication. After 24 to 48 hours, develops catatonic stupor with mutism, immobility, and food refusal. Other signs of benzodiazepine withdrawal are present, but the predominant presentation is catatonic syndrome. Code 6A41 is appropriate, with additional documentation of the specific substance.

Scenario 4: Paradoxical reaction to steroids A patient on high-dose corticosteroid therapy for a medical condition develops catatonic symptoms including catalepsy, mannerisms, and catatonic excitement alternating with periods of stupor. Investigation rules out metabolic, infectious, or structural causes. The temporal relationship with the initiation of corticosteroid therapy and the absence of other explanations justify code 6A41.

Scenario 5: Hallucinogen intoxication A young person with no prior psychiatric history uses LSD and develops immobility, fixed gaze, negativism, and automatic obedience. Symptoms persist beyond the expected period of acute intoxication. Psychiatric evaluation confirms catatonic syndrome without evidence of underlying primary psychotic disorder.

Scenario 6: Reaction to fluoroquinolone antibiotic A patient undergoing treatment with ciprofloxacin for urinary tract infection develops progressive neuropsychiatric symptoms culminating in catatonic presentation with mutism, rigidity, and stupor. Extensive neurological investigation rules out other causes. Discontinuation of the antibiotic results in gradual symptom improvement, confirming the causal relationship.

Criteria that must be present:

Presence of at least three characteristic catatonic symptoms
Clear temporal relationship between substance/medication exposure and symptom onset
Documented evidence of use, intoxication, or withdrawal of the substance
Exclusion of other primary medical or psychiatric causes
Symptoms not better explained by another condition

4. When NOT to Use This Code

Precise differentiation is essential to avoid inadequate coding. Code 6A41 should NOT be used in the following situations:

Neuroleptic Malignant Syndrome (NMS): If a patient taking antipsychotics develops severe muscular rigidity of "lead pipe" type, significant hyperthermia (body temperature above 38°C), marked autonomic instability (blood pressure fluctuations, tachycardia, profuse diaphoresis) and laboratory abnormalities such as marked elevation of CPK, the correct diagnosis is NMS, and code 384289569 should be used. NMS represents a medical emergency with pathophysiology distinct from medication-induced catatonia, although symptom overlap may occur.

Serotonin Syndrome: When a patient develops the characteristic triad of altered mental status, autonomic hyperactivity, and neuromuscular abnormalities (especially hyperreflexia, clonus, and tremor) after exposure to serotonergic agents (SSRIs, SNRIs, MAO inhibitors, tramadol, etc.), the appropriate code is 203881550 for serotonin syndrome. Although agitation and rigidity may be present, the clinical presentation differs significantly from catatonia.

Catatonia associated with primary mental disorder: If the patient has an established diagnosis of schizophrenia, bipolar disorder, or major depression and develops catatonic symptoms in the context of these disorders, even if taking medications, the correct code is 6A40 (Catatonia associated with another mental disorder), not 6A41. The crucial distinction is whether catatonia represents a manifestation of the underlying psychiatric disorder or a reaction to a substance.

Substance-induced delirium: When fluctuation in level of consciousness, disorientation, and attentional deficits predominate, even with psychomotor alterations present, the primary diagnosis is delirium, not catatonia. Catatonia presents with preserved level of consciousness when the patient can be engaged.

Simple intoxication without complete catatonic syndrome: Isolated psychomotor symptoms during intoxication that do not meet criteria for complete catatonic syndrome (minimum of three characteristic symptoms) should be coded as intoxication by the specific substance, not as medication-induced catatonia.

5. Step-by-Step Coding Process

Step 1: Assess diagnostic criteria

Diagnostic confirmation requires systematic evaluation using validated instruments. The Bush-Francis Catatonia Rating Scale (BFCRS) represents the standard tool, assessing 23 catatonic signs. For diagnosis, at least three of the following symptoms are generally required:

Stupor: Absence of psychomotor activity, without active relationship with the environment
Catalepsy: Passive maintenance of posture against gravity
Waxy flexibility: Slight resistance during limb repositioning
Mutism: Absence or minimal verbal response
Negativism: Opposition or non-response to instructions
Posture: Spontaneous and active maintenance of posture against gravity
Mannerisms: Bizarre caricature of normal actions
Stereotypies: Repetitive movements, abnormally frequent
Agitation not influenced by external stimuli
Grimacing: Maintenance of peculiar facial expressions
Echolalia: Repetition of the examiner's words
Echopraxia: Imitation of the examiner's movements

The lorazepam test (benzodiazepine challenge) may aid diagnosis: administration of 1-2 mg of lorazepam intramuscularly or intravenously frequently results in dramatic improvement of catatonic symptoms within 15-30 minutes, confirming the diagnosis.

Step 2: Verify specifiers

Document specific characteristics:

Severity: Mild (symptoms present but functionality partially preserved), moderate (significant functional impairment) or severe (complete incapacity, risk of medical complications).

Duration: Acute (less than 1 month), subacute (1-3 months) or chronic (more than 3 months). In substance-induced catatonia, most cases are acute.

Predominant characteristics: Specify whether symptoms of hypoactivity (stupor, mutism, immobility) or hyperactivity (excitement, agitation) predominate.

Causative substance: Specifically document which substance or medication is implicated.

Step 3: Differentiate from other codes

6A40 vs. 6A41: The fundamental differentiation between Catatonia associated with another mental disorder (6A40) and Catatonia induced by substances or medications (6A41) is based on primary etiology.

Use 6A40 when:

Patient has a diagnosed psychiatric disorder (schizophrenia, bipolar disorder, major depression)
Catatonic symptoms represent a manifestation or complication of this disorder
There is no clear temporal relationship with introduction, increase, or withdrawal of substance
Symptoms persist even after medication adjustments

Use 6A41 when:

Clear temporal relationship between substance exposure and symptoms
Absence of primary psychiatric disorder or catatonic symptoms disproportionate to the underlying disorder
Improvement with substance removal or specific treatment of intoxication/withdrawal
History consistent with known pharmacological effect of the substance

Step 4: Required documentation

Checklist of mandatory information:

[ ] Date and time of onset of catatonic symptoms
[ ] Complete list of catatonic symptoms present
[ ] Score on assessment scale (BFCRS or similar)
[ ] Substance(s) or medication(s) implicated
[ ] Dose, route of administration and pattern of use
[ ] Temporal relationship between exposure and symptoms
[ ] Results of toxicological tests when applicable
[ ] Exclusion of alternative medical causes (laboratory tests, neuroimaging)
[ ] Response to lorazepam test if performed
[ ] Risk assessment (malignant catatonia, medical complications)
[ ] Previous psychiatric history
[ ] Treatments instituted and response

Appropriate documentation: "Patient developed catatonic syndrome characterized by [list specific symptoms] with onset [date/time] after [substance exposure]. BFCRS score: [value]. Toxicological tests confirmed [substance]. Medical investigation ruled out alternative causes. Diagnosis: Catatonia induced by substances or medications (ICD-11: 6A41)."

6. Complete Practical Example

Clinical Case:

A 28-year-old male patient with no significant prior psychiatric history is brought to the emergency department by family members after three days of progressively bizarre behavior. According to collateral information, the patient had attended a recreational event where he consumed a substance later identified as MDMA (ecstasy).

Initial presentation: At the time of evaluation, the patient is in a stupor, with a fixed gaze, unresponsive to verbal commands. He maintains a rigid seated posture, with arms flexed in an unnatural position. When the examiner repositions the upper extremities, mild resistance is observed and the new posture is maintained for several minutes (waxy flexibility). There is no spontaneous or responsive verbalization. Feeding attempts are refused with negative head movements. Episodes of maintained facial grimacing are also observed.

Evaluation performed: Physical examination reveals stable vital signs: temperature 37.2°C, blood pressure 125/80 mmHg, heart rate 88 bpm. Absence of "lead pipe" type muscular rigidity. Neurological examination demonstrates no focal deficits. Pupils are isocoric and photoreactive.

Laboratory tests: normal complete blood count, preserved renal and hepatic function, electrolytes within normal limits, CPK mildly elevated (350 U/L - upper normal limit), but without marked elevation. Urine toxicology test positive for MDMA and cannabis metabolites.

Cranial computed tomography without acute alterations. Electroencephalogram shows nonspecific diffuse slowing, without epileptiform activity.

Application of the Bush-Francis Scale identifies the following symptoms: stupor (present), catalepsy (present), waxy flexibility (present), mutism (present), negativism (present), bizarre posture (present), grimacing (present). Total score: 14 points, compatible with moderate to severe catatonia.

Diagnostic reasoning: The presence of multiple catatonic symptoms (seven criteria identified) in a clear temporal context with MDMA use establishes the diagnosis of substance-induced catatonia. The absence of prior psychiatric history, the acute onset related to substance use, and the exclusion of alternative medical causes (infection, metabolic disorders, structural lesions) strengthen this diagnosis.

Normal temperature, absence of severe rigidity, and only mildly elevated CPK rule out neuroleptic malignant syndrome. The absence of hyperreflexia, clonus, and tremor rule out serotonin syndrome, although MDMA possesses serotonergic properties. The preserved level of consciousness (patient can be briefly engaged during lorazepam challenge test) differentiates from delirium.

Justification for coding: Code 6A41 is appropriate because:

Complete catatonic syndrome is present (multiple diagnostic criteria)
Clear temporal relationship with MDMA intoxication
Laboratory confirmation of the substance
Exclusion of alternative diagnoses
Absence of underlying primary psychiatric disorder

Step-by-Step Coding:

Criteria analysis:

✓ Minimum of three catatonic symptoms: CONFIRMED (seven symptoms present)
✓ Temporal relationship with substance: CONFIRMED (onset 24-48h after MDMA use)
✓ Evidence of exposure: CONFIRMED (positive toxicology test)
✓ Exclusion of medical causes: CONFIRMED (complete investigation negative)
✓ Exclusion of NMS: CONFIRMED (absence of criteria)
✓ Exclusion of serotonin syndrome: CONFIRMED (absence of characteristic triad)

Code selected: 6A41 - Catatonia induced by substances or medications

Complete justification: Patient developed catatonic syndrome characterized by stupor, catalepsy, waxy flexibility, mutism, negativism, bizarre posture, and grimacing, with BFCRS score of 14 points, initiated 24 to 48 hours after confirmed MDMA consumption. Medical investigation excluded infectious, metabolic, structural causes and other neuropsychiatric syndromes. Absence of significant prior psychiatric history. Clinical presentation consistent with known adverse effect of MDMA.

Complementary codes:

Additional code to specify the substance (MDMA intoxication)
Code to document complications if present (dehydration, mild rhabdomyolysis)

7. Related Codes and Differentiation

Within the Same Category:

6A40: Catatonia associated with another mental disorder

When to use 6A40:

Patient with diagnosed schizophrenia develops catatonic episode during psychotic exacerbation
Individual with bipolar disorder presents with catatonia during severe depressive episode
Catatonia emerges as complication of established primary psychiatric disorder
Symptoms persist regardless of medication adjustments

When to use 6A41:

Catatonia develops specifically following introduction, increase, or withdrawal of medication
Clear temporal relationship between substance and symptoms
Absence of primary psychiatric disorder or symptoms disproportionate to underlying disorder
Improvement with removal of causative substance

Main difference: Code 6A40 indicates that catatonia is a manifestation of primary mental disorder, while 6A41 specifies that catatonia results directly from pharmacological effect of substance or medication. The distinction is fundamental to guide treatment: in 6A40, the underlying disorder is treated; in 6A41, the causative substance is removed or adjusted.

Differential Diagnoses:

Neuroleptic Malignant Syndrome (NMS): Differentiated by significant hyperthermia, severe muscular rigidity of "lead pipe" type, pronounced autonomic instability, and marked elevation of CPK (frequently above 1000 U/L). Represents medical emergency with significant mortality if untreated.

Serotonin Syndrome: Characterized by triad of mental alterations, autonomic hyperactivity, and specific neuromuscular abnormalities (hyperreflexia, clonus, tremor). Onset typically more rapid (hours) after serotonergic exposure.

Delirium: Distinguished by fluctuation in level of consciousness, disorientation, and prominent attentional deficits. In catatonia, level of consciousness is preserved when the patient can be engaged.

Depressive stupor: Can mimic catatonia, but lacks characteristic motor signs such as catalepsy, waxy flexibility, and stereotypies. History of progressive depressive symptoms precedes stupor.

Akinetic mutism: Neurological condition with identifiable structural lesion (usually bilateral frontal or diencephalic). Neuroimaging demonstrates causative lesion.

8. Differences with ICD-10

In the ICD-10 classification, substance-induced catatonia did not have a dedicated specific code. Cases were frequently classified under broader categories such as:

ICD-10: F10-F19.xx (Mental and behavioral disorders due to psychoactive substance use), with additional specifiers for psychotic symptoms or other states.

Main changes in ICD-11:

Increased specificity: ICD-11 creates a dedicated code (6A41) exclusively for substance-induced catatonia, recognizing its distinct clinical importance.
Clear separation: Explicit differentiation between catatonia associated with mental disorder (6A40) and substance-induced catatonia (6A41), eliminating ambiguities from ICD-10.
Expanded definition: ICD-11 provides a specific list of causative substances (PCP, cannabis, hallucinogens, cocaine, MDMA) and medications (antipsychotics, benzodiazepines, steroids, disulfiram, ciprofloxacin), better guiding clinical practice.
Improved hierarchical structure: More logical organization within catatonic syndromes facilitates navigation and coding.

Practical impact: More specific coding in ICD-11 allows for:

More precise epidemiological tracking of catatonia induced by specific substances
Identification of emerging patterns related to new substances of abuse
Clearer communication among professionals about etiology
More targeted clinical research on specific treatments
More precise legal documentation in cases of adverse drug reactions

Professionals familiar with ICD-10 should recognize that cases previously coded generically now require the specific code 6A41, significantly improving the granularity of clinical and epidemiological data.

9. Frequently Asked Questions

1. How is substance-induced catatonia diagnosed?

The diagnosis is based on three fundamental pillars: identification of complete catatonic syndrome (minimum of three characteristic symptoms), establishment of clear temporal relationship between substance exposure and symptom onset, and exclusion of alternative causes. The evaluation uses standardized scales such as Bush-Francis Catatonia Rating Scale, detailed clinical examination, toxicological tests when appropriate, and medical investigation to rule out metabolic, infectious, or structural causes. The lorazepam test (administration of benzodiazepine with observation of response) can assist diagnostic confirmation, with dramatic symptom improvement in 15-30 minutes strongly suggesting catatonia.

2. Is treatment available in public health systems?

Treatment of substance-induced catatonia is generally available in public health systems, although the availability of specific resources varies among different regions and institutions. Main interventions include benzodiazepines (especially lorazepam), which are widely available and low-cost medications. In refractory cases, electroconvulsive therapy (ECT) represents highly effective treatment, although its availability is more limited and generally restricted to specialized centers. Management also includes supportive care such as hydration, nutrition, prevention of deep vein thrombosis, and monitoring of medical complications, all available in general hospital services.

3. How long does treatment last?

Treatment duration varies significantly depending on the causative substance, symptom severity, and individual response. In cases related to acute intoxication with short half-life substances, resolution may occur within days to weeks with appropriate treatment. Catatonia related to long-acting medications or accumulation may require weeks to months for complete resolution. Benzodiazepine treatment generally continues until symptom resolution, followed by gradual reduction. The acute phase typically requires hospitalization for one to three weeks, with subsequent outpatient follow-up. Cases related to substance withdrawal may resolve more rapidly once the withdrawal period is overcome and supportive treatment is instituted.

4. Can this code be used in medical certificates?

Yes, code 6A41 can and should be used in medical certificates when appropriate, adequately documenting the patient's clinical condition. In certificates, it is recommended to balance diagnostic accuracy with considerations of confidentiality and stigma. One may opt for descriptions such as "acute neuropsychiatric syndrome" or "psychomotor disorder" in non-specialized documents, reserving complete coding for formal medical documentation. For legal, occupational, or insurance purposes, accurate documentation with ICD-11 code is often necessary. Professionals should consider implications for the patient (employment, insurance, permanent record) when documenting diagnoses related to substance use, always maintaining truthfulness and clinical accuracy.

5. Which substances most commonly cause catatonia?

The substances most frequently implicated include antipsychotics (especially high-potency ones such as haloperidol), phencyclidine (PCP), MDMA and related drugs, cannabis (particularly in vulnerable users), hallucinogens such as LSD and mescaline, and cocaine. Among non-psychiatric medications, high-dose steroids, fluoroquinolone antibiotics (ciprofloxacin), disulfiram, and paradoxically benzodiazepines (especially during withdrawal) can cause catatonia. Abrupt withdrawal of benzodiazepines after prolonged use represents a particularly important cause. Novel psychoactive agents ("synthetic drugs") continuously emerge as potential causes, requiring continuous vigilance.

6. Can substance-induced catatonia be fatal?

Yes, substance-induced catatonia can be potentially fatal if not treated appropriately. Complications include severe dehydration, malnutrition, deep vein thrombosis with pulmonary embolism, rhabdomyolysis with acute renal failure, aspiration pneumonia, and malignant catatonic syndrome (characterized by fever, autonomic instability, and rapid deterioration). Mortality is significantly reduced with early recognition and appropriate treatment. Patients require close medical monitoring, adequate hydration, nutrition (often via nasogastric tube), thrombosis prophylaxis, and vigilance for complications. Early recognition and aggressive intervention are critical to prevent adverse outcomes.

7. How to differentiate antipsychotic-induced catatonia from neuroleptic malignant syndrome?

Differentiation is crucial but can be challenging. Neuroleptic malignant syndrome is characterized by severe muscular rigidity "lead pipe" type (non-waxy flexibility), significant hyperthermia (temperature frequently above 39-40°C), pronounced autonomic instability (extreme blood pressure and heart rate fluctuations, profuse diaphoresis), and marked CPK elevation (typically above 1000 U/L, often much higher). Antipsychotic-induced catatonia may present with normal or mildly elevated temperature, less severe rigidity with waxy flexibility, more stable vital signs, and normal or mildly elevated CPK. NMS represents a medical emergency with significant mortality, requiring immediate antipsychotic discontinuation, intensive supportive measures, and specific treatments (dantrolene, bromocriptine). In practice, there is a spectrum between conditions, and ambiguous cases should be treated aggressively as NMS for safety.

8. Can patients develop recurrent catatonia if reexposed to the substance?

Yes, individuals who developed catatonia induced by a specific substance present increased risk of recurrence if reexposed to the same substance or related substances. This "sensitization" phenomenon is particularly relevant for antipsychotic medications, where patients with a history of induced catatonia may present recurrent episodes even with lower doses. Careful documentation of previous episodes is essential to prevent inadvertent reexposure. Patients and family members should be educated about substances to avoid. In medical records, allergies and adverse reactions should include history of induced catatonia, guiding future prescriptions. For patients requiring continuous antipsychotic treatment after a catatonic episode, careful selection of alternative agent, minimum effective doses, and close monitoring are essential.

Conclusion:

Accurate coding of substance- or medication-induced catatonia using ICD-11 code 6A41 represents a fundamental element of appropriate clinical care. This article provided comprehensive guidance on when and how to apply this code, differentiating it from related conditions, and highlighting its importance for documentation, treatment, and research. Healthcare professionals should maintain vigilance for this potentially serious syndrome, recognizing its variable presentation and implementing appropriate interventions based on accurate diagnostic coding. The transition from ICD-10 to ICD-11 offers an opportunity to significantly improve diagnostic specificity and, consequently, clinical outcomes for patients affected by this complex condition.

External References

This article was prepared based on reliable scientific sources:

References verified on 2026-02-03

Substance or Medication-Induced Catatonia

Share